Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertension incidence is rising globally, affecting approximately 30% of the U.S. population.
• Blood pressure control remains suboptimal, with only 36.8% achieving recommended levels (< 140/90 mmHg).
• Elevated blood pressure significantly increases risks of cardiovascular events and stroke.

Purpose of the Study:

• To evaluate the efficacy and tolerability of fixed-dose combination therapy for hypertension management.
• To highlight the benefits of amlodipine combined with olmesartan or valsartan as initial therapy.
• To assess the impact of these combinations on amlodipine-induced edema and metabolic profiles.

Main Methods:

• Review of recent FDA-approved fixed-dose combination therapies for hypertension.
• Analysis of clinical data on amlodipine/olmesartan and amlodipine/valsartan combinations.
• Assessment of safety, tolerability, and specific side effect profiles, including edema and metabolic neutrality.

Main Results:

• Fixed-dose combinations of amlodipine with olmesartan or valsartan are effective and well-tolerated treatments for hypertension.
• These combinations significantly reduce the incidence of edema compared to amlodipine monotherapy.
• Metabolically neutral components make these combinations suitable for patients with diabetes or metabolic syndrome.

Conclusions:

• Fixed-dose combination therapy is recommended for stage 2 hypertension when monotherapy is insufficient.
• Amlodipine/olmesartan and amlodipine/valsartan offer improved efficacy, tolerability, and patient acceptance.
• These combinations are advantageous for hypertensive patients with comorbidities like diabetes and metabolic syndrome.